Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darvadstrocel in pediatric Crohn's disease with complex perianal fistula
NL-OMON55133Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Jun 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of darvadstrocel in Crohn's disease and anal fistula, sponsored by Takeda. Primary endpoint: Combined remission at Week 24. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
darvadstrocel
03
Conditions
Crohn's diseaseanal fistula
Beyond the preview
Go deeper on NL-OMON55133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55133.